InMed Pharmaceuticals (INM) Notes Payables (2021 - 2022)
InMed Pharmaceuticals (INM) posted quarterly Notes Payables of $29312.0 for Q1 2022, down 50.0% quarter-over-quarter from $58624.0 in Q4 2021.
InMed Pharmaceuticals (INM) Notes Payables (2021 - 2022) Analysis & Trends
InMed Pharmaceuticals' Notes Payables history runs 2 years deep, the most recent figure standing at $29312.0 for Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | InMed Pharmaceuticals | 6.38 Mn | 1.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 29,312.00 |
| Dec 31, 2021 | 58,624.00 |